Table 2

Baseline characteristics of participants allocated to the VTP group or routine care plus individual voluntary use of mindfulness-based home exercises on CD

All participantsVTP groupControl group
(n=71)(n=36)(n=35)
Demographics
 Age, years53.9 (9.1)53.0 (9.4)54.9 (8.9)
 Women56 (78.9)28 (77.8)28 (80.0)
 Married/living with partner46 (64.8)23 (63.9)23 (65.7)
 Education >12 years37 (52.1)18 (50.0)19 (54.3)
 Paid work28 (39.4)14 (38.9)14 (40.0)
Disease and function
 Disease duration, years16.2 (12.7)14.4 (11.3)18.0 (14.0)
 Symptoms duration, years19.1 (12.8)18.7 (13.1)19.6 (12.7)
 Diagnosis
  Rheumatoid arthritis42 (59.2)23 (63.9)19 (54.3)
  Ankylosing spondylitis15 (21.1)6 (16.7)9 (25.7)
  Psoriatic arthritis7 (9.9)3 (8.3)4 (11.4)
  Other inflammatory arthritis7 (9.8)4 (11.1)3 (8.7)
Comorbidity48 (72.7)26 (76.5)22 (68.8)
PGA (0–10, 0=no activity)4.6 (1.7)4.6 (1.6)4.5 (1.9)
Medication
 Analgesics35 (49.3)19 (52.8)16 (45.7)
 NSAIDs33 (46.5)20 (55.6)13 (37.1)
 Cortisone26 (36.6)14 (38.9)12 (34.3)
 DMARDs (non-biological)34 (47.9)18 (50.0)16 (45.7)
 Biological therapy19 (26.8)7 (19.4)12 (34.3)
GHQ-20 >2323 (32.4)13 (36.1)10 (28.6)
MHAQ (0–3, 0=good function)0.5 (0.5)0.4 (0.3)0.6 (0.7)
Physical activity>2 h/week25 (35.2)14 (38.9)11 (31.4)
  • Values are reported as number (%) or mean (SD).

  • CD, control group; DMARDs, disease-modifying antirheumatic drugs; GHQ-20, General Health Questionnaire-20; MHAQ, Modified Health Assessment Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; PGA, patient global assessment of disease activity; VTP, Vitality Training Programme.